# Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

> **NCT00019448** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Stage IV Melanoma
- Recurrent Melanoma

## Interventions

- **DRUG:** gp100 antigen
- **DRUG:** interleukin-2

## Key facts

- **NCT ID:** NCT00019448
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** — (—)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019448, "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00019448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*